Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Animals
Antineoplastic Agents
/ chemistry
Cell Line, Tumor
Cell Proliferation
/ drug effects
Colonic Neoplasms
/ drug therapy
Coumarins
/ chemistry
Doxorubicin
/ analogs & derivatives
Drug Synergism
Female
Half-Life
Humans
Liposomes
/ chemistry
Mice
Mice, Inbred BALB C
Neovascularization, Physiologic
/ drug effects
Oligopeptides
/ chemistry
Polyethylene Glycols
/ chemistry
Survival Rate
Tissue Distribution
Xenograft Model Antitumor Assays
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 07 2019
02 07 2019
Historique:
received:
12
03
2019
accepted:
17
06
2019
entrez:
4
7
2019
pubmed:
4
7
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Galbanic acid (Gba), a sesquiterpene coumarin, with strong antiangiogenic activity could serve as an excellent anti-cancer agent. However, Gba is a poor water-solube which hampered its clinical application. In this study, a pegylated liposomal Gba (PLGba) with HSPC/Cholesterol/mPEG
Identifiants
pubmed: 31267009
doi: 10.1038/s41598-019-45974-7
pii: 10.1038/s41598-019-45974-7
pmc: PMC6606580
doi:
Substances chimiques
Antineoplastic Agents
0
Coumarins
0
Liposomes
0
Oligopeptides
0
liposomal doxorubicin
0
Polyethylene Glycols
3WJQ0SDW1A
arginyl-glycyl-aspartic acid
78VO7F77PN
Doxorubicin
80168379AG
galbanic acid
9OFS0HWC92
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9527Commentaires et corrections
Type : ErratumIn
Références
J Control Release. 2013 Dec 28;172(3):782-94
pubmed: 24075927
J Control Release. 2015 Aug 10;211:1-9
pubmed: 25989603
Pharm Res. 2002 Mar;19(3):265-9
pubmed: 11934232
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12
pubmed: 9539785
Aptechn Delo. 1962 May-Jun;12:28-34
pubmed: 13866469
Int J Pharm. 2013 Dec 31;458(2):324-33
pubmed: 24148663
BMC Cancer. 2010 Oct 05;10:529
pubmed: 20923544
Nanoscale. 2015 Nov 28;7(44):18584-94
pubmed: 26489965
Int Rev Cell Mol Biol. 2008;270:181-224
pubmed: 19081537
J Nat Prod. 2003 Jul;66(7):1022-37
pubmed: 12880330
Oncol Rep. 2015 Oct;34(4):1825-34
pubmed: 26238930
Int J Nanomedicine. 2015 Feb 02;10:975-99
pubmed: 25678787
Signal Transduct Target Ther. 2018 Mar 16;3:7
pubmed: 29560283
Expert Opin Drug Deliv. 2015;12(9):1475-99
pubmed: 25843160
Nat Nanotechnol. 2007 Dec;2(12):751-60
pubmed: 18654426
Planta Med. 2011 Jan;77(1):52-4
pubmed: 20560115
Cancer Res. 1995 Sep 1;55(17):3752-6
pubmed: 7641188
Int J Mol Sci. 2012;13(8):9959-70
pubmed: 22949841
Int J Biol Macromol. 2015 Nov;81:308-15
pubmed: 26253511
Pharm Biol. 2013 Dec 13;:
pubmed: 24328450
Eur J Pharm Biopharm. 2014 May;87(1):170-7
pubmed: 24333400
Angew Chem Int Ed Engl. 2007;46(19):3571-4
pubmed: 17394271
Nucl Med Biol. 2006 Nov;33(8):953-61
pubmed: 17127167
J Control Release. 2015 Dec 28;220(Pt A):308-315
pubmed: 26526970
Methods Enzymol. 2007;426:463-503
pubmed: 17697896
Nucl Med Biol. 2004 Jan;31(1):11-9
pubmed: 14741566
Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):188-193
pubmed: 29037813
Pharm Res. 2011 Mar;28(3):597-609
pubmed: 21063754
Clin Ther. 2016 Jul;38(7):1551-66
pubmed: 27158009
Phytochemistry. 2007 Feb;68(4):554-61
pubmed: 17196626
J Control Release. 2015 Dec 28;220(Pt A):275-286
pubmed: 26518722
Dermatology. 2003;207(1):43-7
pubmed: 12835547
Nanoscale. 2018 Dec 13;10(48):22720-22724
pubmed: 30488936
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
J Pharm Pharm Sci. 2000 May-Aug;3(2):234-58
pubmed: 10994037
J Biol Chem. 1959 Mar;234(3):466-8
pubmed: 13641241
Drug Resist Updat. 2005 Dec;8(6):381-402
pubmed: 16309948
Curr Pharm Biotechnol. 2016;17(8):662-72
pubmed: 27087491
Small. 2008 Aug;4(8):1240-6
pubmed: 18666163
Cytometry A. 2017 Aug;91(8):760-766
pubmed: 27077940
Adv Drug Deliv Rev. 2013 Jan;65(1):71-9
pubmed: 23088862
Mol Cancer Ther. 2008 Dec;7(12):3670-84
pubmed: 19074844
Int J Pharm. 2016 Sep 10;511(1):236-244
pubmed: 27363937